Abstract 2260P
Background
Trastuzumab has improved the prognosis in patients with HER2-positive breast cancer, but it can induce left ventricular dysfunction with reduced ejection fraction or HF during treatment. Dapagliflozin is a SGLT2i with cardio-renal benefits. In the DAPA-HF trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin decreased the risk of worsening HF events and cardiovascular death in patients with HF and reduced ejection fraction. Recent preclinical systematic review indicated that Berberine significantly reduces myocardial infarct size and the incidence of ventricular arrhythmia, improves cardiac function, ameliorates myocardial apoptosis.
Methods
Human fetal cardiomyocytes (HFC cell line) were exposed to subclinical concentration of trastuzumab (200 nM) alone or co-incubated with Berberine (200 mM) or Dapagliflozin (50 nM) or both in combination for 48 h. After the incubation period, we performed the following tests: cell viability, apoptosis, expression of NLRP3 inflammasome, methylglyoxal and leukotrienes-B4. Expression of pAMPK was analyzed through western blot. Moreover, quantification of IL-6 was performed through ELISA method.
Results
Berberine and Dapagliflozin significantly increased the cell viability of cardiomyocytes exposed to Trastuzumab. When combined, Berberine and Dapagliflozin increased synergistically cell viability of cardiac cells (p<0.001 vs Trastuzumab). Cell apoptosis was reduced of 32.5, 41.8 and 72.7% for berberine, dapagliflozin and both combined (vs trastuzumab group). Methylglyoxal,a marker of AGEs, was strongly reduced compared to untreated cells. Western blot analysis clearly demonstrates that pAMPK was induced by berberine and Dapagliflozin, improving mitochondrial metabolism. Intracellular levels of IL-6 were reduced of 46.3, 62.7 and 86.3% for berberine, dapagliflozin and both combined (vs trastuzumab group).
Conclusions
Berberine and Dapagliflozin in combination induces an anti-inflammatory phenotype to myocardial cells through the reduction of biomarkers involved in heart failure and apoptosis.
Legal entity responsible for the study
Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale.
Funding
Ministero della Salute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2299P - Mebendazole enhances the anticancer effect of irinotecan and check-point inhibitor in vitro and in vivo
Presenter: Sharmineh Mansoori
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Presenter: Eun Joo Kang
Session: Poster session 08